-
-
-
-
-
-
-
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
-
-
-
-
-
-
-
Fortress Biotech unit Cyprium agrees to sell rare disease voucher for $205M
-
-
-
-
-
-
-
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
-
-
-
-
-
-
-
Fortress Biotech unit begins phase 3 dotinurad gout trials
-
-
-
-
-
-
-
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Announces Emrosi Data Analysis to be Presented at SDPA
-
-
-
-
-
-
-
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
-
1,179,530 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

